Optimum prednisolone usage in patients with biliary atresia postportoenterostomy.
OBJECTIVE
Prednisolone is used routinely after portoenterostomy (PE) in patients with biliary atresia (BA). The authors reviewed their patients with BA post-PE to assess prednisolone protocols.


METHODS
Severity of fibrosis at PE (moderate or severe), age at PE (30-70 days), size of bile ductules in the fibrotic biliary remnant at the porta hepatis (>100 microm), and type of BA (uncorrectable type) were used as criteria for selecting 63 subjects from our patients with BA post-PE. Subjects were divided into 5 groups according to prednisolone dosage: group 1, no prednisolone; groups 2 to 4, single courses of intravenous prednisolone commencing on day 7 post-PE administered in decreasing dose for 3 days each as follows: group 2, 6, 4, and 2 mg; group 3, 10, 5, and 2.5 mg; group 4, 20, 15, 10, 5, and 2.5 mg; group 5, same as group 4, but stool color was used to monitor bile excretion and a course was restarted from 20 mg whenever stools began to turn pale. If necessary, single courses were repeated until serum total bilirubin was less than 2.0 mg/dL. Protocol efficacy was assessed by comparing the number of patients who became jaundice free, the period taken to become jaundice free, and the incidence of side effects related to prednisolone.


RESULTS
The number of patients who became jaundice free in the no prednisolone group (group 1, 7/12 or 58.3%) was not significantly different from the number in the single-course groups (group 2, 8/12 or 66.6%; group 3, 10/13 or 76.9%; and group 4, 11/15 or 73.3%). The number in the stool-monitored group (group 5, 10/11 or 90.9%) was significantly greater (P < .05). The mean period taken to become jaundice free in group 1 (82.6 +/- 29.1 days) was not significantly different from the single-course groups (group 2, 74.5 +/- 29.3 days; group 3, 49.6 +/- 19.8 days; and group 4, 48.3 +/- 26.0 days). The mean period taken in the stool-monitored group (group 5, 33.3 +/- 6.4 days) was significantly shorter (P < .05). The number of subjects who developed cholangitis after becoming jaundice free was not significantly different (group 1, 2/7; group 2, 2/8; group 3, 2/10; group 4, 2/11; group 5, 2/10). There were no prednisolone-related complications identified in any subject.


CONCLUSIONS
These results provide strong evidence that large-dose prednisolone therapy with stool color monitoring of bile flow has a positive impact on the time taken for patients with BA post-PE to become jaundice free and the number of patients who remain jaundice free.
Kobayashi
Hiroyuki
H
Department of Pediatric Surgery, Juntendo University School of Medicine, Tokyo 113-8421, Japan. koba@med.juntendo.ac.jp
Yamataka
Atsuyuki
A
Koga
Hiroyuki
H
Okazaki
Tadaharu
T
Tamura
Tsuyoshi
T
Urao
Masahiko
M
Yanai
Toshihiro
T
Lane
Geoffrey J
GJ
Miyano
Takeshi
T
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001656:Biliary Atresia / Q000150:complications / Q000601:surgery*; D001663:Bilirubin / Q000097:blood; D002761:Cholangitis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002985:Clinical Protocols; D005243:Feces; D005260:Female; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D007565:Jaundice / Q000097:blood / Q000188:drug therapy; D008297:Male; D011171:Portoenterostomy, Hepatic; D011182:Postoperative Care; D011239:Prednisolone / Q000008:administration & dosage*
D000893:Anti-Inflammatory Agents; D011239:Prednisolone; D001663:Bilirubin